Table 1.
Group I-PCR and serological results for patients with ZIKV infection.
| Group | ID/Sample Number | Country of Infection | DPSO | PRNT (ZIKV) | ZIKV RT-PCR | ZIKV IgM Ratio (ELISA) | ZIKV IgG Ratio (ELISA) | ZIKV RAI (Last Dilution) | IgA Ratio (ELISA) | DENV IgM * | DENV IgG * |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | P1/S1 | Venezuela | 32 | ND | Pos (u) | Neg | Neg | Neg | ND | Neg | |
| I | P1/S2 | 58 | ND | ND | Pos (2.0) | Pos (3.9) | L (35.9) | Equiv (1.0) | ND | Pos | |
| I | P2/S1 | Honduras | 7 | ND | Pos (s) | Neg | Neg | Neg | Neg | Neg | |
| I | P2/S2 | 21 | Pos | ND | Pos (2.5) | Pos (3.9) | L (33.4) | Neg | ND | Pos | |
| I | P3/S1 | Dominican Republic | 3 | Pos | Pos (u) | Neg | Neg | Neg | Neg | Neg | |
| I | P3/S2 | 12 | Pos | Neg (s) | Pos (3.5) | Pos (1.3) | L (18.2) | Pos (2.6) | Neg | Neg | |
| I | P4/S1 | Sexual transmission | 0 | ND | Pos (u) | Neg | Neg | Neg | ND | Pos | |
| I | P4/S2 | 12 | ND | Neg (s) | Pos (1.4) | Pos (2.9) | L (15.6) | Pos (5.3) | ND | Pos | |
| I | P5/S1 | Brazil | 0 | ND | Pos (u) | Neg | Neg | Neg | Neg | Pos | |
| I | P5/S2 | 32 | ND | ND | Pos (1.7) | Pos (2.8) | L (38.6) | Neg | ND | Pos | |
| I | P6/S1 | Unk | 4 | ND | Pos (b,u) | Neg | Neg | Neg | Neg * | Pos * | |
| I | P6/S2 | 26 | ND | ND | Pos (1.2) | Pos (3.2) | L (38.8) | Neg | Neg * | Pos * | |
| I | P7/S1 | Brazil | 4 | ND | Pos (b) | Neg | Neg | Neg | Neg * | Pos * | |
| I | P7/S2 | 7 | ND | ND | Neg | Pos (6.9) | Equiv (53.6) | Pos (4.2) | Neg * | Pos * | |
| I | P8/S1 | Honduras | 4 | ND | Pos (u) | Neg | Pos (3.3) | Equiv (40.6) | Neg | Neg | Pos |
| I | P9/S1 | Honduras | 3 | Pos | Pos (u) | Neg | Pos (6.4) | Inc (72.6) | Pos (2.7) | ND | Pos |
| I | P10/S1 | Venezuela | 11 | Pos | Pos (u) | Neg | Pos (4.6) | Equiv (41.3) | Pos (2) | Neg | Pos |
| I | P11/S1 | Mexico | 1 | ND | Pos (u) | Neg | Neg | Neg | ND | Neg | |
| I | P12/S1 | Colombia | 7 | Pos | Pos (u) | Pos (6.4) | Pos (2.7) | L (24.3) | Pos (2.9) | Neg | Neg |
| I | P13/S1 | Colombia | 3 | ND | Pos (u) | Pos (2.4) | Pos (2.2) | Equiv (54.6) | Pos (1.2) | ND | Pos |
| I | P14/S1 | Martinica | 7 | ND | Pos (u) | Neg | Neg | Neg | Neg * | Pos * | |
| I | P14/S2 | 21 | ND | ND | Pos | Equiv (1.0) | Inc (71.3) | Neg | Neg * | Pos * | |
| I | P15/S1 | Brazil | 12 | ND | Pos (u) | Neg | Pos (6.2) | Inc (73.7) | Pos (4.6) | Neg * | Pos * |
| I | P16/S1 | Brazil | 20 | ND | Pos (u) | Neg | Pos (5.9) | Inc (64.6) | Pos (1.7) | Neg * | Pos * |
| I | P17/S1 | Brazil | 3 | ND | Pos (u) | Neg | Neg | Neg | Neg * | Neg * | |
| I | P18/S1 | Brazil | 5 | ND | Pos (b,u) | Neg | Neg | Neg | Neg * | Neg * | |
| I | P19/S1 | Unk | 19 | ND | Pos (u) | Pos (1.4) | Neg | Pos (1.2) | Neg * | Neg * | |
| I | P20/S1 | Brazil | 3 | ND | Pos (u) | Neg | Neg | Neg | Neg * | Pos * | |
| I | P21/S1 | Bolivia | 6 | ND | Pos (u) | Neg | Pos (5.1) | Equiv (51.0) | Pos (4.7) | Neg | Pos |
| I | P21/S2 | 27 | Pos | ND | Neg | Pos (5.7) | Equiv (57.8) | Pos (1.2) | Neg | Pos | |
| I | P22/S1 | Dominican Republic | 7 | ND | Pos (u) | Neg | Pos (7.1) | Equiv (53.9) | Pos (2.6) | Neg | Pos |
| I | P22/S2 | 36 | ND | ND | Neg | Pos (6.2) | H (80.4) | Neg | ND | Pos | |
| I | P23/S1 | unk | 9 | ND | Pos (u) | Neg | Neg | Neg | Neg * | Neg * | |
| I | P24/S1 | unk | 10 | ND | Pos (u) | Neg | Neg | Neg | Neg * | Pos * | |
| I | P25/S1 | Colombia | <20 | ND | Pos (s) | Neg | Pos (2.8) | Equiv (59) | Pos (1.2) | Pos | Pos |
| I | P26/S1 | Venezuela | 4 | ND | Pos (u) | Neg | Pos (5.0) | Equiv (43.5) | Pos (3.4) | Pos | Pos |
| I | P27/S1 | Brazil | 3 | ND | Pos (u) | Neg | Neg | Neg | Neg * | Neg * | |
| I | P27/S2 | Brazil | 9 | ND | ND | Pos (4.6) | Neg | Pos (2.6) | Pos * | Neg * | |
| I | P27/S3 | 261 | ND | ND | Neg | Pos (1.4) | H (72.8) | Neg | Neg * | Pos * | |
| I | P28/S1 | Brazil | 5 | ND | Pos (u) | Neg | Neg | Neg | Neg * | Neg * | |
| I | P28/S2 | 21 | ND | ND | Pos (3.5) | Pos (1.7) | L (29.4) | Pos (4.4) | Pos * | Pos * | |
| I | P29/S1 | Colombia | 6 | ND | Pos (u) | Pos (2.6) | Equiv (1.0) | Equiv (54.8) | Pos (4.8) | Neg * | Pos * |
| I | P29/S2 | 24 | ND | ND | Pos (2.0) | Pos (1.5) | L (33.4) | Pos (4.3) | Pos * | Pos * |
DPSO—Days post illness onset; Equiv—Equivocal; Inc—inconclusive; L—low avidity; ND—not determined; Neg—negative result; Pos—positive result; PRNT—plaque reduction neutralization test; RAI—Relative avidity index; unk—unknown; (b)—blood sample; (s)—serum sample; (u)—urine sample. DENV IgM and IgG: the samples marked * were tested by IIF, the remaining by ELISA.